<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-164
Date of Submission: 2025-08-06

This report was submitted by a Nurse from Davis Ltd Medical Center concerning patient ANON-PX-3560. The subject is a 63-year-old male with a significant medical history including asthma, coronary artery disease, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Lisinopril administered via the Intramuscular route at a dosage of 289mg, initiated on 2025-07-22 for Hypertension and discontinued on 2025-07-28; Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 81mg, initiated on 2025-07-22 for Neuropathic pain and discontinued on 2025-07-28.

On approximately 2025-07-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Anaphylaxis, Maculopapular Rash. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed successful and advised allow. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed land and advised meeting. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Skin growth majority cost trade amount market common. Management administration partner party after. Treat view design never individual customer.</data>
report_id: ADR-2025-164
report_date: '2025-08-06'
patient_details:
  patient_id: ANON-PX-3560
  gender: Male
  relevant_history:
  - asthma
  - coronary artery disease
  - type 2 diabetes
  age_at_reaction: 63
suspected_drugs:
- drug_name: Lisinopril
  dosage: 289mg
  route_of_administration: Intramuscular
  start_date: '2025-07-22'
  indication_for_use: Hypertension
  end_date: '2025-07-28'
- drug_name: Gabapentin
  dosage: 81mg
  route_of_administration: Oral
  start_date: '2025-07-22'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-07-28'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-07-28'
  severity: Life-threatening
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed successful and advised allow.
- symptom_name: Anaphylaxis
  onset_date: '2025-07-28'
  severity: Severe
  outcome: Recovered
  intervention_required: false
- symptom_name: Maculopapular Rash
  onset_date: '2025-07-28'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed land and advised meeting.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Negative dechallenge
  naranjo_score: 3
reporting_facility: Davis Ltd Medical Center
reporter_type: Nurse
notes: Skin growth majority cost trade amount market common. Management administration
  partner party after. Treat view design never individual customer.
